The purpose of the ILCA Guidances is to broaden awareness and deepen knowledge about recent, relevant research diagnosis and treatment of liver cancer. Expand ILCA’s thought leadership through generating additional guidance documentation offering an invaluable resource in the correct management of liver cancer.

Transarterial Chemoembolisation (TACE) Consensus Guidance

ILCA is developing the Transarterial Chemoembolisation (TACE) Consensus Guidance. A multi-disciplinary working group of oncologists, surgeons, hepatologists and scientists is working together to write clinical questions and literature search for the TACE manuscript based on the findings of evidence-based medicine. This guidance generated by these experts will provide a set of recommendations and unique documentation offering an invaluable resource in the correct management of liver cancer and helping patients with the best care options.

ILCA TACE Consensus Guidance will be finalised and published in 2022.

Biomarker Development for Hepatocellular Carcinoma

There is an urgent clinical need for new biomarkers in hepatocellular carcinoma, including better tools for early tumor detection and prediction of response to systemic therapies.

The International Liver Cancer Association has put together an exceptional team of experts led by Drs. Villanueva and Singal, who recently published a white paper with recommendations on the design, interpretation and reporting of biomarker studies in hepatocellular carcinoma. This addresses the much needed guidance for academia and industry on the best approach to develop new biomarkers for this devastating disease.

ILCA Systemic Therapy Guidance
The past few years have witnessed huge progress in the treatment of advanced HCC and the therapeutic landscape has been transformed. In order to provide comprehensive, up-to-date and readily accessible information about the latest treatment, ILCA have developed on-line guidance. The guidance has been launched at the ILCA 2020 conference during which Tim Meyer, UCL Cancer Institute, University College in London, UK and Robin Kate Kelley, Associate Professor University of California, San Francisco, USA  have presented the key features as:
  • Interactive therapeutic algorithm
  • Summary of and links to key data that provide the evidence base for current therapy
  • Focussed discussion on clinical decision making according to specific clinical contexts


Your email address will not be published.

  • ILCA School of Liver Cancer. 26-27 May, 2022. Chicago, USA.
  • ILCA Single Topic Workshop. 9-10 June, 2022. Paris, France.
  • ILCA Webinar: Tumor heterogeneity in HCC analyzed by single cell analysis. 16 June, 2022.
  • ILCA Annual Conference. 1-4 September, 2022. Madrid, Spain.